↓ Skip to main content

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

Overview of attention for article published in Cardiovascular Diabetology, January 2014
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#32 of 1,175)
  • High Attention Score compared to outputs of the same age (95th percentile)

Mentioned by

news
2 news outlets
blogs
3 blogs
twitter
5 tweeters

Citations

dimensions_citation
180 Dimensions

Readers on

mendeley
281 Mendeley